A study comparing oral hydroxychloroquine and supportive treatment with supportive treatment alone for management of IgA nephropathy
Not Applicable
- Conditions
- Health Condition 1: N289- Disorder of kidney and ureter, unspecified
- Registration Number
- CTRI/2021/07/034929
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Adult patients(=18 years AND <60 years age) with biopsy proven primary IgA nephropathy
2.Persistent urinary protein creatinine ratio >1g/g but less than 3.5g/g
3.eGFR=45 ml/min/1.73m2 as calculated by the chronic kidney disease epidemiology collaboration creatinine equation (CKD-EPI)
4.Has been on ACEi/ARB therapy for at-least 6 months in maximal tolerated dose
Exclusion Criteria
1.Use of immunosuppression in the past 6 months
2.IgAN requiring immunosuppression like crescentic IgAN or IgA vasculitis
3.Current or planned pregnancy or lactation
4.Concomitant systemic disease like diabetes, chronic liver disease, malignancy, any cardiac or cerebrovascular disease
5.Retinopathy
6.G6PD deficiency
7.Unwilling to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •The primary outcome studied will be the proportion of patients who achieve remission(complete/partial) at the end of 6 months in both the groups. <br/ ><br>Timepoint: At 6 months
- Secondary Outcome Measures
Name Time Method The secondary outcome will be (1) Difference in the percentage reduction in proteinuria between the two groups (2) Difference in renal survival defined as decline in eGFR of 40% or progression to end stage renal disease(ESRD) at the end of 6 months between the two groups <br/ ><br>Timepoint: At 6 months